Baricitinib
Mar 17, 2020
Moderna’s COVID-19 vaccine; AcelRx buys TetraPhase; Breakthrough designation to Baricitinib
Moderna announces dozing of first patient with its mRNA1273 vaccine The pharmaceutical company, Moderna, has been developing a vaccine for the treatment of COVID-19. The vaccine is an mRNA-1273 is developed by scientist at NAID, in collaboration with Moderna, and the manufacturing of the vaccine for Phase I clin...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
